Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.37 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.37 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8956691 | 0.83 | PDE2A (0.47) | PDE2ATRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL9996686 | 0.74 | PDE2A (0.49) | PDE2AKDM4EBACE1CYP1A2CYP2D6 | |
| Hydroxyamine SCHEMBL28660962 | 0.74 | PDE2A (0.49) | PDE2AKDM4ESCN10ABACE1CYP1A2 | |
| SCHEMBL28440353 | 0.74 | MGLL (0.42) | PDE2AKDM4ETRPV6ORAI1ORAI2 | |
| SCHEMBL29122745 | 0.73 | POLB (0.38) | KDM4EBACE1TGM2EPHX2SCN4A | |
| SCHEMBL13967832 | 0.73 | TP53 (0.35) | KDM4ETRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL25026056 | 0.72 | CYP1A1 (0.43) | PDE2AKDM4ESCN10ABACE1EPHX2 | |
| SCHEMBL4076004 | 0.72 | CES2 (0.46) | PDE2AKDM4EBACE1TGM2EPHX2 | |
| SCHEMBL13523746 | 0.72 | PDE2A (0.46) | PDE2AKDM4EBACE1EPHX2SCN4A | |
| SCHEMBL30233883 | 0.72 | CYP1A1 (0.43) | PDE2AKDM4ESCN10ABACE1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067921-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067921-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140155404-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155404-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| US-8680104-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680104-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| EP-1734966-B1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORP (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-1734966-B1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORP (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20120295912-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295912-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2012-11-22 | — | — | US | disclosed |
| US-8268826-B2 | 5-({4-[(3S)-4-(5-bromo-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine; inflammatory diseases, immune diseases and viral infections; HIV | INCYTE CORPORATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268826-B2 | 5-({4-[(3S)-4-(5-bromo-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine; inflammatory diseases, immune diseases and viral infections; HIV | INCYTE CORPORATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268826-B2 | 5-({4-[(3S)-4-(5-bromo-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine; inflammatory diseases, immune diseases and viral infections; HIV | INCYTE CORPORATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-7678798-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678798-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678798-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20050261310-A1 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261310-A1 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | CCR5, CCR2, CXCR5 | PDE2A 659/4885KDM4E 3844/4885TRPV6 171/4885 |
| US-20140155404-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | CCR5, CCR2, CXCR5 | PDE2A 659/4885KDM4E 3844/4885TRPV6 171/4885 |
| US-20120295912-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | CCR5, CCR2, CXCR5 | PDE2A 659/4885KDM4E 3844/4885TRPV6 171/4885 |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | CCR5, CCR2, CXCR5 | PDE2A 659/4885KDM4E 3844/4885TRPV6 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.